Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
Recruiting
Observational Study
Multiple Sclerosis, Relapsing-Remitting
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Study type
- Observational
- Participants needed
- 24 (estimated)
- Sponsor
- Amsterdam UMC, location VUmc · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to study the long-term effects of autologous hematopoietic stem cell transplantation (aHSCT) in people with highly active relapsing-remitting multiple sclerosis. The study will evaluate the following items:
1. Disease activity
2. Safety and tolerability of aHSCT
3. Changes in the immune system
Participants will be subjected to frequent visits for five year…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patients approved for treatment with aHSCT in the Netherlands in accordance with the Dutch criteria for aHSCT treatment for RRMS
Exclusion Criteria:
* Contra-indications for treatment with aHSCT such as known hypersensitivity to the medication used for aHSCT
* Clinically…
Contacts